GlassScriptPhysician profile
John F Greene
NPI 1063453520
$1,780.37
in general payments reported to CMS, 2019-2025
34 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $228 · 2021: $176 · 2022: $429 · 2023: $161 · 2024: $263 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.75 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $133.34 | 2021-2025 | |
| Astellas Pharma US INC | $126.02 | 2023-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $107.02 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.56 | 2021-2025 | |
| Sage Therapeutics, LLC | $83.98 | 2020-2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $81.53 | 2019 | |
| Hologic Sales and Service, LLC | $78.43 | 2020-2023 | Fluent Fluid Management System, Aptima |
| Exeltis, USA INC. | $75.69 | 2021-2023 | Slynd |
| Dexcom, INC. | $69.98 | 2025 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $63.38 | 2019-2020 | |
| Axsome Therapeutics, INC. | $49.74 | 2024-2025 | Auvelity |
| Coopersurgical, INC. | $44.02 | 2019-2020 | |
| Gynesonics, INC. | $43.50 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Agile Therapeutics, INC. | $36.27 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $35.99 | 2024-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $34.76 | 2024-2025 | Myfembree |
| Pfizer INC. | $33.59 | 2019-2024 | |
| Millicent US INC | $27.99 | 2025 | Femlyv |
| Mylan Pharmaceuticals INC. | $26.94 | 2020-2021 | |
| Roche Diagnostics Corporation | $20.12 | 2019 | |
| Lupin INC. | $18.97 | 2020 | |
| Shield Therapeutics INC | $17.42 | 2024 | |
| Exact Sciences Corporation | $16.72 | 2025 | Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $15.86 | 2021 | |
| Evofem Biosciences, INC. | $15.12 | 2021 | |
| Corium, LLC | $14.96 | 2023 | Azstarys |
| Davol INC. | $14.95 | 2022 | |
| Avion Pharmaceuticals | $14.60 | 2021 | |
| Meditrina | $13.79 | 2024 | |
| Radius Health, INC. | $13.66 | 2024 | Tymlos |
| Minerva Surgical, INC | $12.87 | 2023 | |
| Duchesnay USA Incorporated | $12.45 | 2019 | |
| Gen-Probe, INC. | $6.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.